• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

2019 年冠状病毒病在墨西哥的生存情况:一项关于相关因素相互作用的队列研究。

Coronavirus Disease-2019 Survival in Mexico: A Cohort Study on the Interaction of the Associated Factors.

机构信息

Department of Clinical Research, Hospital Infantil de México Federico Gómez, Mexico City, Mexico.

Centre for Research in Emerging Diseases, Hospital Infantil de México Federico Gómez, Mexico City, Mexico.

出版信息

Front Public Health. 2021 Jul 27;9:660114. doi: 10.3389/fpubh.2021.660114. eCollection 2021.

DOI:10.3389/fpubh.2021.660114
PMID:34386471
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8353107/
Abstract

The pandemic caused by the new coronavirus Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) is currently affecting more than 200 countries. The most lethal clinical presentation is respiratory insufficiency, requiring attention in intensive care units (ICU). The most susceptible people are over 60 years old with comorbidities. The health systems organization may represent a transcendental role in survival. To analyze the correlation of sociodemographic factors, comorbidities and health system organization variables with survival in cases infected by SARS-CoV-2 during the first 7 months of the pandemic in Mexico. The cohort study was performed in a health system public basis from March 1st to September 30th, 2020. The included subjects were positive for the SARS-CoV-2 test, and the target variable was mortality in 60 days. The risk variables studied were: age, sex, geographic distribution, comorbidities, health system, hospitalization, and access to ICU. Bivariate statistics (-test), calculation of fatality rates, survival analyses and adjustment of confusing variables with Cox proportional-hazards were performed. A total of 753,090 subjects were analyzed, of which the 52% were men. There were 78,492 deaths (10.3% of general fatality and 43% inpatient). The variables associated with a higher risk of hospital mortality were age (from 60 years onwards), care in public sectors, geographic areas with higher numbers of infection and endotracheal intubation without management in the ICU. The variables associated with a lower survival in cases affected by SARS-CoV-2 were age, comorbidities, and respiratory insufficiency (with endotracheal intubation without care in the ICU). Additionally, an interaction was observed between the geographic location and health sector where they were treated.

摘要

由新型冠状病毒严重急性呼吸综合征冠状病毒 2 型(SARS-CoV-2)引起的大流行目前正在影响 200 多个国家。最致命的临床表现是呼吸功能不全,需要在重症监护病房(ICU)中进行治疗。最易感染的人群是 60 岁以上合并有并发症的人群。卫生系统的组织可能在生存方面起着至关重要的作用。

为了分析社会人口统计学因素、合并症和卫生系统组织变量与墨西哥大流行期间前 7 个月感染 SARS-CoV-2 的病例的生存情况之间的相关性。

该队列研究是在 2020 年 3 月 1 日至 9 月 30 日期间在一个基于公共卫生系统的基础上进行的。纳入的研究对象是 SARS-CoV-2 检测呈阳性的患者,目标变量是 60 天内的死亡率。研究的风险变量有:年龄、性别、地理分布、合并症、卫生系统、住院和 ICU 入住。进行了单变量统计分析(-检验)、病死率计算、生存分析和 Cox 比例风险混杂变量调整。

共分析了 753090 名患者,其中 52%为男性。共有 78492 人死亡(一般病死率为 10.3%,住院患者病死率为 43%)。与住院死亡率较高相关的变量有年龄(60 岁以上)、在公共部门接受治疗、感染人数较多的地理区域以及在 ICU 中没有管理的气管插管。

与 SARS-CoV-2 感染病例生存情况较差相关的变量有年龄、合并症和呼吸功能不全(伴有气管插管但没有在 ICU 中进行治疗)。此外,还观察到地理位置和治疗所在的卫生部门之间存在交互作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6f2c/8353107/c03285a5c83f/fpubh-09-660114-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6f2c/8353107/dfc543e0b4bc/fpubh-09-660114-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6f2c/8353107/c03285a5c83f/fpubh-09-660114-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6f2c/8353107/dfc543e0b4bc/fpubh-09-660114-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6f2c/8353107/c03285a5c83f/fpubh-09-660114-g0002.jpg

相似文献

1
Coronavirus Disease-2019 Survival in Mexico: A Cohort Study on the Interaction of the Associated Factors.2019 年冠状病毒病在墨西哥的生存情况:一项关于相关因素相互作用的队列研究。
Front Public Health. 2021 Jul 27;9:660114. doi: 10.3389/fpubh.2021.660114. eCollection 2021.
2
Survival analysis and mortality predictors of COVID-19 in a pediatric cohort in Mexico.墨西哥儿科队列中 COVID-19 的生存分析和死亡预测因素。
Front Public Health. 2022 Dec 16;10:969251. doi: 10.3389/fpubh.2022.969251. eCollection 2022.
3
Intensive care for seriously ill patients affected by novel coronavirus sars - CoV - 2: Experience of the Crema Hospital, Italy.重症监护治疗新型冠状病毒 SARS-CoV-2 感染患者:意大利克雷马医院的经验。
Am J Emerg Med. 2021 Jul;45:156-161. doi: 10.1016/j.ajem.2020.08.005. Epub 2020 Aug 16.
4
IMPACT OF COMORBIDITIES IN MEXICAN SARS-COV-2-POSITIVE PATIENTS: A RETROSPECTIVE ANALYSIS IN A NATIONAL COHORT.墨西哥新冠病毒检测呈阳性患者中合并症的影响:一项全国队列的回顾性分析
Rev Invest Clin. 2020;72(3):151-158. doi: 10.24875/RIC.20000207.
5
Determinants of survival after severe acute respiratory syndrome coronavirus 2 infection in Mexican outpatients and hospitalised patients.墨西哥门诊和住院患者严重急性呼吸综合征冠状病毒 2 感染后生存的决定因素。
Public Health. 2020 Dec;189:66-72. doi: 10.1016/j.puhe.2020.09.014. Epub 2020 Sep 30.
6
Association of Race and Ethnicity With Comorbidities and Survival Among Patients With COVID-19 at an Urban Medical Center in New York.纽约市一家城市医疗中心的 COVID-19 患者种族与合并症及生存率的关系。
JAMA Netw Open. 2020 Sep 1;3(9):e2019795. doi: 10.1001/jamanetworkopen.2020.19795.
7
Predicting Mortality Due to SARS-CoV-2: A Mechanistic Score Relating Obesity and Diabetes to COVID-19 Outcomes in Mexico.预测因 SARS-CoV-2 导致的死亡率:一个将肥胖和糖尿病与墨西哥 COVID-19 结局相关联的机制评分。
J Clin Endocrinol Metab. 2020 Aug 1;105(8). doi: 10.1210/clinem/dgaa346.
8
Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.评估 BIO101 预防 COVID-19 肺炎患者呼吸恶化的疗效和安全性(COVA 研究):一项随机对照试验研究方案的结构化总结。
Trials. 2021 Jan 11;22(1):42. doi: 10.1186/s13063-020-04998-5.
9
Outcomes following SARS-CoV-2 infection in liver transplant recipients: an international registry study.肝移植受者感染 SARS-CoV-2 后的结局:一项国际注册研究。
Lancet Gastroenterol Hepatol. 2020 Nov;5(11):1008-1016. doi: 10.1016/S2468-1253(20)30271-5. Epub 2020 Aug 28.
10
Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.COVID-19 住院成人患者使用伊马替尼的安全性和疗效:一项随机对照试验研究方案的结构化总结。
Trials. 2020 Oct 28;21(1):897. doi: 10.1186/s13063-020-04819-9.

引用本文的文献

1
Comorbidities and their association with COVID-19 mortality in Mexico between January 2020 and August 2021.2020 年 1 月至 2021 年 8 月期间墨西哥合并症及其与 COVID-19 死亡率的关系。
PLoS One. 2024 Apr 17;19(4):e0296895. doi: 10.1371/journal.pone.0296895. eCollection 2024.
2
Spatial Survival Model for COVID-19 in México.墨西哥新冠肺炎的空间生存模型
Healthcare (Basel). 2024 Jan 24;12(3):306. doi: 10.3390/healthcare12030306.
3
Risk Factors for Mortality of Hospitalized Adult Patients with COVID-19 Pneumonia: A Two-Year Cohort Study in a Private Tertiary Care Center in Mexico.

本文引用的文献

1
[Epidemiology of COVID-19 in Mexico: from the 27th of February to the 30th of April 2020].[墨西哥2019冠状病毒病流行病学:2020年2月27日至4月30日]
Rev Clin Esp. 2020 Nov;220(8):463-471. doi: 10.1016/j.rce.2020.05.007. Epub 2020 May 27.
2
Factors associated with death in children with COVID-19 in Mexico.墨西哥 COVID-19 患儿死亡的相关因素。
Gac Med Mex. 2020;156(6):516-522. doi: 10.24875/GMM.M21000478.
3
SARS-CoV-2 infection in children, clinical characteristics, diagnostic findings and therapeutic interventions at a tertiary care center in Riyadh, Saudi Arabia.
墨西哥一家私立三级护理中心的一项为期两年的队列研究:住院成人 COVID-19 肺炎患者死亡的危险因素。
Int J Environ Res Public Health. 2023 Mar 2;20(5):4450. doi: 10.3390/ijerph20054450.
4
Survival analysis and mortality predictors of COVID-19 in a pediatric cohort in Mexico.墨西哥儿科队列中 COVID-19 的生存分析和死亡预测因素。
Front Public Health. 2022 Dec 16;10:969251. doi: 10.3389/fpubh.2022.969251. eCollection 2022.
5
[Survival in pediatric patients with pneumonia in coronavirus disease 2019].[2019年冠状病毒病肺炎患儿的生存情况]
Rev Med Inst Mex Seguro Soc. 2022 Aug 31;60(5):511-516.
沙特阿拉伯利雅得一家三级护理中心的儿童 SARS-CoV-2 感染、临床特征、诊断结果和治疗干预措施。
J Infect Public Health. 2021 Apr;14(4):446-453. doi: 10.1016/j.jiph.2020.12.034. Epub 2021 Jan 14.
4
Social inequalities and COVID-19 mortality in the city of São Paulo, Brazil.巴西圣保罗市的社会不平等与 COVID-19 死亡率
Int J Epidemiol. 2021 Jul 9;50(3):732-742. doi: 10.1093/ije/dyab022.
5
Case fatality ratio of COVID-19 patients requiring invasive mechanical ventilation in Mexico: an analysis of nationwide data.墨西哥需要有创机械通气的新冠病毒疾病患者的病死率:一项全国数据的分析
Crit Care. 2021 Feb 16;25(1):68. doi: 10.1186/s13054-021-03485-w.
6
COVID-19 first anniversary review of cases, hospitalization, and mortality in the UK.COVID-19 首例周年回顾:英国的病例、住院和死亡情况。
Expert Rev Respir Med. 2021 Aug;15(8):973-978. doi: 10.1080/17476348.2021.1890035. Epub 2021 Feb 26.
7
COVID-19 case fatality risk by age and gender in a high testing setting in Latin America: Chile, March-August 2020.高检测环境下拉丁美洲年龄和性别与 COVID-19 病死率的关系:智利,2020 年 3 月至 8 月。
Infect Dis Poverty. 2021 Feb 3;10(1):11. doi: 10.1186/s40249-020-00785-1.
8
Characterisation of the first 250,000 hospital admissions for COVID-19 in Brazil: a retrospective analysis of nationwide data.巴西 25 万例 COVID-19 住院患者的特征:全国范围内数据的回顾性分析。
Lancet Respir Med. 2021 Apr;9(4):407-418. doi: 10.1016/S2213-2600(20)30560-9. Epub 2021 Jan 15.
9
[Sex/gender differences in COVID-19 lethality: what the data say, and do not say].[新冠病毒病致死率中的性别差异:数据所表明及未表明的情况]
Epidemiol Prev. 2020 Sep-Dec;44(5-6 Suppl 2):400-406. doi: 10.19191/EP20.5-6.S2.145.
10
Prospective Latin American cohort evaluating outcomes of patients with COVID-19 and abnormal liver tests on admission.前瞻性拉丁美洲队列研究评估 COVID-19 患者入院时肝功能异常的结局。
Ann Hepatol. 2021 Mar-Apr;21:100298. doi: 10.1016/j.aohep.2020.100298. Epub 2021 Jan 7.